Rochester, NY — September 8, 2025 — Regenerelle®, a global leader in the manufacturing and distribution of Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) and exosomes derived from WJ-MSCs, today announced the public release of its full response to the U.S. Food and Drug Administration (FDA) Untitled Letter dated May 22, 2023.

The disclosure is being made by AT Venture Center, the parent company of Regenerelle, LLC, the regenerative biotherapeutic manufacturing and distribution arm of the company providing stem cells and exosome products to its subsidiaries and distributors serving an extensive connected network of more than 4,000 regenerative medicine and aesthetics professionals worldwide, including MedSpas, orthopedic and pain clinics, wound care centers, and aesthetic practices. [Read more…]

Los Angeles, CA – September 4, 2025 – As industry scrutiny intensifies over cosmetic products making bold but unverified “exosome” claims, Biogenomics, a biotech company advancing regenerative aesthetics, has announced performance breakthroughs for its flagship innovation, Genovia. Unlike competitors who emphasize inflated particle counts, Genovia is engineered through a patented lactoferrin-enhanced process that delivers scientifically validated quality, safety, and functional performance.

“Exosomes aren’t about chasing numbers — they’re about results providers can trust and patients can see,” said a Biogenomics spokesperson. “That’s the standard Genovia delivers.” [Read more…]